Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Replimune

Replimune?uq=kzBhZRuG
2015 FOUNDED
PUBLIC STATUS
41-50 EMPLOYEES
REPL STOCK SYMBOL
$16.91 SHARE PRICE (As of Friday Closing)
Description

Provider of therapeutic treatment intended to increase the effectiveness of cancer treatment. The company's Immulytic platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune activating proteins to the tumor and draining lymph nodes.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Stock Exchange
NAS
Primary Office
  • 18 Commerce Way
  • Woburn, MA 01801
  • United States

+1 (781) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Replimune’s full profile, request a free trial.

Replimune Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$14.99 - $16.91 $503M $16.30 281K 30.8M

Replimune Financials Summary

In Thousands,
USD
TTM
31-Mar-2018
FY 2018
31-Mar-2018
FY 2017
31-Mar-2017
FY 2016
31-Mar-2016
Revenue 463
EBITDA (19,881) (19,881) (7,607) (1,007)
Net Income (19,702) (19,702) (7,704) (718)
Total Assets 65,151 65,151 22,819
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Replimune Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Replimune‘s full profile, request access.

Request full access to PitchBook

Replimune Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Replimune‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Replimune Executive Team (10)

Name Title Board
Seat
Contact
Info
Robert Coffin Ph.D Co-Founder, Chief Executive Officer & Board Member
Colin Love Chief Operating Officer
Tess Schmalbach Executive Medical Director
Pamela Esposito Chief Business Officer
Philip Astley-Sparke Co-Founder & Executive Chairman
You’re viewing 5 of 10 executives. Get the full list »

Replimune Board Members (10)

Name Representing Role Since Contact
Info
Brett Zbar MD Foresite Capital Management Board Observer 000 0000
Hyam Levistsky Self Board Member 000 0000
Jason Rhodes Atlas Venture Board Member 000 0000
Joseph Slattery Self Board Member 000 0000
Kapil Dhingra MD Forbion Capital Partners Board Member & Special Advisor 000 0000
You’re viewing 5 of 10 board members. Get the full list »